News

Article

EMPOWERing the Next Generation

Author(s):

Erica Koenig, PhD

An expert discusses recent research evaluating a selective M4 positive allosteric modulator for the treatment of schizophrenia.

CONFERENCE REPORTER

Erica Koenig, PhD, gives an overview of Cerevel Therapeutics and discusses EMPOWER, a phase 2 clinical trial evaluating emraclidine for the treatment of schizophrenia. Koenig presented this research in a poster presentation at Psych Congress 2023.

Dr Koenig is program lead of emraclidine and senior director of global clinical development at Cerevel Therapeutics.

Related Videos
Julyuela/AdobeStock
tardive dyskinesia
tardive dyskinesia
tardive dyskinesia
meds pills
covid
ADHD
covid-19
ADHD
covid
Related Content
Ronsik/AdobeStock
February 21st 2025

The Week in Review: February 17-21

Megan McSweeney
Treating ‘Morally Objectionable’ Patients
September 27th 2021

Treating ‘Morally Objectionable’ Patients

James L. Knoll IV, MD
pregnancy
February 18th 2025

Planned Induction of Labor in a Patient With Acute Late-Pregnancy Psychosis: A Case Report

Cecilia A. Westbrook, MD, PhD Meredith Spada, MD Elizabeth M. Hovis, MD Jacob Larkin, MD Alexandra Nicholas, MD Luke Swider, MD Jonathan Yadlosky, MD Joseph S. DeRenzo, MD Adam P. Dunmore, MD Jennifer L. Kloesz, MD, FAAP Linda Dudas, RNC, MSN, CNL John Silipigni, MSW, MBA Priya Gopalan, MD
More Than Postpartum Depression: Addressing Maternal Mental Health Through the Life Cycle
May 11th 2021

More Than Postpartum Depression: Addressing Maternal Mental Health Through the Life Cycle

Anita H. Clayton, MD
schizophrenia
February 17th 2025

Xanomeline-Trospium as a Novel Agent for Treatment of Psychosis in Schizophrenia

Caitlin Leconte, MD Albert Dickan, MD Haley Schuster, MD Mark Mullen, MD Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP
Tasty Cat/AdobeStock
February 14th 2025

Long-Term Efficacy and Safety of Xanomeline and Trospium in Schizophrenia: EMERGENT-5 Trial Findings

Megan McSweeney
© 2025 MJH Life Sciences

All rights reserved.